Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback